May Adiponectin be considered as a NovelCardiometabolic Biomarker?

This study was designed to evaluate the interaction between total adiponectin (ADPN)and metabolic syndrome (MetS) on cardiac changes in 135 subjects with and withoutMetS, subgrouped according to normal or low ADPN. Left ventricular internal diameter(LVID/h), LV mass (LVM), LVM index (LVMI), interventricular septal thickness (IVST),relative wall thickness (RWT) and LV ejection fraction (EF) by echocardiography anddiastolic parameters, by pulsed-wave Doppler were calculated. BMI, LVM, LVMI, LVID/h, IVST and RWT values were significantly (p<0.05) higher inboth groups with low ADPN. Prevalence of left ventricular hypertrophy (p<0.001) andcoronary artery disease (p<0.01) was significantly higher in both low ADPN groups.LVMI correlated directly with BMI (p<0.001), (p<0.001), MetS (p<0.001) and inverselywith ADPN (p<0.0001). ADPN and BMI resulted independently associated with LVMI.In conclusion, our data suggest that hypoadiponectinemia might be considered a novel“cardiometabolic biomarker”. Accordingly, circulating ADPN might become a newtarget in the management of cardiometabolic syndrome.